Eli Lilly and Company (NYSE:LLY) has stockpiled $1.5 billion worth of inventory of its experimental oral weight-loss drug, orforglipron, according to a regulatory filing on Thursday.

This significant inventory buildup is in anticipation of a decision by the U.S. Food and Drug Administration (FDA) expected in April. The inventory value has seen a substantial increase from last year’s nearly $550 million.

The FDA has awarded the weight-loss pill a fast-track review voucher, potentially shortening the approval timeline to one or two months, a sharp reduction from the usual 10 to 12 months required for most new drugs.

Eli Lilly has previously said it expects to have sufficient supply to roll out its highly anticipated weight-loss pill across multiple countries at nearly the same time, pending U.S. approval.

Medicare Boost For Obesity Drugs

Eli ...